Entelos, Inc. (LSE: ENTL), the leader in predictive disease simulation for pharmaceutical, health-care and consumer
products applications, today announced that it has entered into an agreement with the U.S. Food and Drug Administration
(FDA) to use the Entelos((reg))Cardiovascular PhysioLab((reg))to assess the cardiovascular safety and efficacy of a
specific drug class and a set of drugs within that class. The compound class and specific set of drugs were not
disclosed.
    The Company's Cardiovascular PhysioLab platform is a comprehensive large-scale computer simulation of cholesterol
regulation, atherogenesis, and cardiovascular risk. It has been used by Entelos for multiple pharmaceutical customers to
simulate and predict the effects of drugs in patients and patient populations, evaluate novel drug targets, test
combination therapies, identify and interpret biomarker patterns, and predict a drug's long-term biological effects.
    "Although the modern controlled clinical trial is still the international gold standard for evaluating safety and
efficacy of new therapies, rare and serious adverse events may only appear after a drug has been administered to a large
heterogeneous population, long after it has been approved," said Janet Woodcock, M.D., director of FDA's Center for Drug
Evaluation and Research. "Having information that may be predictive of likely adverse events or that can help to explain
the biological mechanisms leading to adverse events in certain patient types could be extremely valuable. This project
will thus test the predictive value of using a dynamic, mechanistic computer model of cardiovascular disease processes
and a large virtual patient population for detecting rare adverse events."
    A broad range of "virtual patients" will be generated using Entelos' cardiovascular platform and used for
simulations to test the cardiovascular safety and efficacy of multiple drugs. Results will be compared to existing
clinical trial data collected by the FDA from multiple drug sponsors. Insights will help to inform the FDA on key
decisions concerning the effects of novel drugs on cardiovascular disease processes.
    "We believe that Entelos is uniquely positioned to deliver a high impact project to the FDA in this most significant
area of drug safety," said James Karis, President and CEO of Entelos. "We look forward to prospectively predicting the
results, both safety and efficacy, of ongoing cardiovascular trials before their submission for approval, and to helping
determine whether adverse events are due to specific compounds or to an entire drug class. We believe that this could
make an impact not only on drugs for cardiovascular indications, but for any drugs with potential effects on the
cardiovascular system."
     For more information: 
 Entelos, Inc.
 Jill Fujisaki, Vice President, Investor Relations      Tel: +1-650-572-5400
                                                                            
 KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
 Capel Irwin/David Anderson                         Tel +44 (0) 20 4718 8900
                                                                            
 Buchanan Communications
 Lisa Baderoon / Mary-Jane Johnson                    Tel +44-0-20-7466-5000
     Notes to Editors 
     About Entelos 
    Entelos, Inc. ( www.entelos.com) is a US-based life sciences company applying next-generation predictive
technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its
proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and
more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of
personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical,
health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Entelos Regs Charts.